Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 37Advanced Breast Cancer 5Neoplasm Metastasis 4Neoplasms 2The Neoadjuvant Therapy 1Solid Tumor, Adult 1Recurrent Uterine Corpus Carcinoma 1Hormone Receptor-positive Advanced Breast Cancer 1Hormone Receptor Positive Advanced Breast Cancer 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1HR Positive/HER-2 Negative Breast Cancer 1Estrogen Receptor-positive Breast Cancer 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Neoplasm Female 1Breast Diseases 1Breast Carcinoma In Situ 1Breast Cancer Organoids 1Brain Neoplasms 1

Interventions

Cyclophosphamide 2Vinorelbine 1Radiotherapy 1Radiomics 1Radiation 1Pharmacogenomic Testing 1Paclitaxel 1Microbubbles 1Magnetic Resonance Spectroscopy 1Fulvestrant 1Fluorouracil 1Epirubicin 1Docetaxel 1Cryosurgery 1Cisplatin 1Capecitabine 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Ductal, Breast × Fulvestrant × Clear all
NCT02983071 2023-02-15

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

G1 Therapeutics, Inc.

Phase 1/2 Unknown
102 enrolled
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast

Data powered by HemOnc (CC BY 4.0) Colophon âš¡